このアイテムのアクセス数: 5818
| タイトル: | 去勢抵抗性前立腺癌に対しドセタキセルを使用した52例の予後因子の検討 |
| その他のタイトル: | Analysis of Prognostic Factor in 52 Castration-Resistant Prostate Cancer Treated with Docetaxel |
| 著者: | 齋藤, 允孝  畑中, 祐二 今西, 正昭 大関, 孝之 橋本, 潔 杉本, 公一 江佐, 篤宣 梶川, 博司 安田, 宗生 山本, 豊 植村, 天受 |
| 著者名の別形: | Saitou, Yoshitaka Hatanaka, Yuji Imanishi, Masaaki Ohzeki, Takayuki Hashimoto, Kiyoshi Sugimoto, koichi Esa, Atsunobu Kajikawa, Hiroshi Yasuda, Muneo Yamamoto, Yutaka Uemura, Hirotsugu |
| キーワード: | Castration-resistant prostate cancer Docetaxel Prognostic factor |
| 発行日: | Jan-2012 |
| 出版者: | 泌尿器科紀要刊行会 |
| 誌名: | 泌尿器科紀要 |
| 巻: | 58 |
| 号: | 1 |
| 開始ページ: | 7 |
| 終了ページ: | 11 |
| 抄録: | The prognostic factor was retrospectively analyzed in 52 castration-resistant prostate cancer treated with docetaxel (DTX) in our institutions from April, 2006 to August, 2009. The treatment outcomes were decided with prostate specific antigen (PSA) progression-free survival and overall survival. These were calculated by Kaplan-Meier methods and tested with Log-ranktest. Median PSA progression-free survival was 8.8 months and median overall survival was 24.1 months. Prognostic factors on PSA progression were PSA value before DTX treatment and rate of PSA decrement after DTX treatment. Prognostic factors on overall survival were Gleason score (GS), PSA value before DTX treatment, rate of PSA decrement after DTX treatment and positive of bone metastasis in Log-ranktest. Odds ratio of PSA ≧20 ng/ml before DTX treatment was 2.99 and PSA decreasing rate ＜30% was 3.65. These were statistically significant (p ＜0.001) riskfactors in the overall survival. |
| 著作権等: | 許諾条件により本文は2013-02-01に公開 |
| URI: | http://hdl.handle.net/2433/153014 |
| PubMed ID: | 22343736 |
| 出現コレクション: | Vol.58 No.1 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。